James Matcham

Vice President, Innovative Statistics

James Matcham is Vice President, Innovative Statistics, at Cytel. James joined Cytel in 2020 bringing with him a strong track record in clinical development and the application of modern statistical methods to decision-making, including the design, analysis, reporting, and interpretation of clinical trials and observational studies for regulatory approval.

James began his career as a Research Fellow at the Applied Statistics Research Unit at the University of Kent, UK. He went on to complete 21 years with Amgen, where he worked on the development and regulatory/reimbursement approval of many of their biotechnology products while representing the company at regulatory submissions in the US and the EU. This was followed by seven years as VP, Early Clinical Biometrics at AstraZeneca where he transformed the Global Early Clinical Biometrics team responsible for early Phase I and II clinical trial design, decision-making, and analysis.

James has a master’s degree in Statistics from Imperial College London and is a Chartered Statistician of the Royal Statistical Society.  His interests include adaptive trial design, the application of Bayesian methods, and quantitative decision-making.